Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: MGI Pharma

Executive Summary

MGI Pharma: Decision Network Committee of the National Cancer Institute has voted in favor of funding and conducting human clinical trials of MGI 114, the lead analog among the company's acylfulvenes, MGI Pharma announces July 25. A clinical trials agreement between NCI and the company has not yet been completed. MGI Pharma states that the NCI trial would complement ongoing Phase I research of MGI 114 in cancer patients, which the company initiated in December...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS028602

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel